Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

Miguel Martín, Aňa Lluch, Miguel Ángel Seguí, A. Ruíz, Manuel Ramos, Encarna Adrover, Álvaro Rodríguez-Lescure, Regina Große, Lourdes Calvo, Concepción Fernández‐Chacón, Montserrat Roset, A. Antón, Dolores Isla, Purificación Martínez del Prado, L. Iglesias, J. Załuski, Àngels Arcusa, José Manuel López-Vega, Montserrat Muñoz-Mateu, J. R. Mel

Annals of Oncology, 2006